Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, March 25, 2019
[ Mon, Mar 25th 2019
] - WOPRAI
[ Mon, Mar 25th 2019
] - WOPRAI
[ Mon, Mar 25th 2019
] - WOPRAI
Fri, March 22, 2019
[ Fri, Mar 22nd 2019
] - WOPRAI
[ Fri, Mar 22nd 2019
] - WOPRAI
[ Fri, Mar 22nd 2019
] - WOPRAI
[ Fri, Mar 22nd 2019
] - WOPRAI
[ Fri, Mar 22nd 2019
] - WOPRAI
[ Fri, Mar 22nd 2019
] - WOPRAI
[ Fri, Mar 22nd 2019
] - WOPRAI
[ Fri, Mar 22nd 2019
] - WOPRAI
[ Fri, Mar 22nd 2019
] - WOPRAI
[ Fri, Mar 22nd 2019
] - WOPRAI
[ Fri, Mar 22nd 2019
] - WOPRAI
[ Fri, Mar 22nd 2019
] - WOPRAI
[ Fri, Mar 22nd 2019
] - WOPRAI
[ Fri, Mar 22nd 2019
] - WOPRAI
Thu, March 21, 2019
[ Thu, Mar 21st 2019
] - WOPRAI
[ Thu, Mar 21st 2019
] - WOPRAI
[ Thu, Mar 21st 2019
] - WOPRAI
[ Thu, Mar 21st 2019
] - WOPRAI
[ Thu, Mar 21st 2019
] - WOPRAI
Matt Phipps Downgraded (BIIB) to Hold on, Mar 21st, 2019
Matt Phipps of William Blair, Downgraded "Biogen Inc." (BIIB) to Hold on, Mar 21st, 2019.
Matt has made no other calls on BIIB in the last 4 months.
There are 4 other peers that have a rating on BIIB. Out of the 4 peers that are also analyzing BIIB, 3 agree with Matt's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Adnan Butt of "Guggenheim" Downgraded from Strong Buy to Hold and Decreased Target to $325 on, Friday, February 22nd, 2019
- Ian Somaiya of "BMO Capital" Initiated at Hold and Held Target at $322 on, Friday, February 22nd, 2019
- Thomas Shrader of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $346 on, Thursday, February 21st, 2019
This is the rating of the analyst that currently disagrees with Matt
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $401 on, Wednesday, December 19th, 2018
